Cooley, Jingtian & Gongcheng and King & Wood Mallesons advised YZY Biopharma, while Sidley and Merits & Tree acted as legal counsel for the sole sponsor...
Wuhan YZY Biopharma’s HK$176 Million Initial Public Offering
ImmuneOnco Biopharmaceuticals’ HK$319 Million IPO
Cooley and JunHe advised ImmuneOnco Biopharmaceuticals on the offering, and Kirkland & Ellis and Jingtian & Gongcheng advised the joint sponsors and underwriters. ImmuneOnco Biopharmaceuticals announced...
Laekna’s HK$791 Million Initial Public Offering
Davis Polk, Jingtian & Gongcheng and Harney Westwood advised Laekna, while Cooley and Commerce & Finance Law Offices advised the sole sponsor and the underwriters. Laekna,...
Seven and Eight Biopharmaceuticals’ License Agreement with Eikon Therapeutics
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
Impact Therapeutics’ Global Partnership with Eikon Therapeutics
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
Roche’s Acquisition of Zion Pharma’s Lead Program Title
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
Keymed Biosciences’ US$400 Million Hong Kong IPO
O’Melveny & Myers and Cooley LLP advised Keymed Biosciences Inc. on the deal, while Kirkland & Ellis advised the joint sponsors and underwriters. Keymed Biosciences Inc....
Peijia Medical Limited’s Listing On The Hong Kong
Herbert Smith Freehills has advised Morgan Stanley Asia Limited and Huatai Financial Holdings as joint sponsors. O’Melveny & Myers LLP and and Jingtian & Gongcheng advised...